| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4727 | Silagaba132 | Silicon-Containing GABA Derivative, Treating Neuropathic Pain without Central-Nervous-System-Related Side Effects |
|
| DCC4728 | Silagaba161 | Silicon-Containing GABA Derivative, Treating Neuropathic Pain without Central-Nervous-System-Related Side Effects |
|
| DCC4729 | Sila-ibuprofen | Novel COX-I and COX-II inhibitor with four times higher solubility in physiological media and a lower melting enthalpy than ibuprofen |
|
| DCC4730 | Simfibrate | Peroxisome proliferator |
|
| DCC4731 | Sinapine Sulfate | Antioxidant and antimicrobial agent, counteracting mitochondrial oxidative stress in cardiomyocytes |
|
| DCC4732 | Sipi-6360 | Novel D2/5-HT2A Receptor Dual Antagonist |
|
| DCC4733 | Sipi-7623 | Novel farnesoid X receptor antagonist |
|
| DCC4734 | Sirt1-a2 | Novel SIRT1 Activator |
|
| DCC4735 | Sirt1-enhancer-a03 | First-in-class apolipoprotein E4 (ApoE4)-targeted sirtuin1 (SirT1) enhancer, normalizing sirtuin 1 levels and improving cognition in an Alzheimer's disease mouse model |
|
| DCC4736 | Sirt1-i5 | Novel SIRT1 Inhibitor, showing potent effect on prostate cancer cell line |
|
| DCC4737 | Sirt1-in-4bb | Novel SIRT1 inhibitor, inducing apoptosis in HCT116 human colon carcinoma cells partially by activating p53 |
|
| DCC4738 | Sirt2-in-6f | Potent and selective inhibitor of SIRT2 |
|
| DCC4739 | Sirt3 Inhibitor P6 | Novel selective SIRT3 inhibitor, exhibiting SIRT3 inhibitory selectivity with IC50 value of 7.2 µM over SIRT1 (32.6 µM) and SIRT2 (33.5 µM), showing potent inhibitory activity against a group of MLLr leukemic cell lines |
|
| DCC4740 | Sir-tz | Novel in situ tetrazine ligation reactive silicon-rhodamine dye |
|
| DCC4741 | Sitafloxacin | Potent broad spectrm fluoroquinolone antibiotic |
|
| DCC4742 | Sitafloxacin Monohydrate | Fluoroquinolone antibiotic, acting as antibacterial, antineoplastic, anti-Infective agents, Inhibiting DNA-gyrase and topoisomerase |
|
| DCC4743 | Si-w052 | Novel inhibitor of lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α and interleukin (IL)-6 on microglia, exhibiting anti-inflammatory activity through ER-stress-mediated autophagy, significantly inducing the conversion ratio of LC3 II/I and |
|
| DCC4744 | Sj1008066 | Novel inhibitor of MAGE-A11 with robust activity in TR-FRET for disrupting MAGE-A11:PCF11 interactionm being cell permeable and having improved activity in the TR-FRET assay (IC50 0.13 µM) |
|
| DCC4745 | Sj3366 | Unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1), also inhibiting HIV-2 |
|
| DCC4746 | Sj521054 | Novel inhibitor of MAGE-A11 with robust activity in TR-FRET for disrupting MAGE-A11:PCF11 interaction (IC50 0.40 μM) |
|
| DCC4747 | Sj572710 | Novel Inhibitor of the Disordered Protein, p27(Kip1) |
|
| DCC4748 | Sj-bis | Novel selective MDMX antagonist |
|
| DCC4749 | Sjf-0628 | Novel BRAF-targeting PROTAC, inducing efficient and potent degradation of mutant BRAF but sparing BRAFWT, inhibiting cell growth in mutant-BRAF driven cancer cells |
|
| DCC4750 | Sjf-1521 | Novel selective EGFR degrader |
|
| DCC4751 | Sjf-1528 | Novel potent EGFR degrader, being capable of penetrating the cell membrane, also degrading an exon-20 insertion mutant form of EGFR (ASV duplication) |
|
| DCC4752 | Sjg-136 | Novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity |
|
| DCC4753 | Sjp-l-5 | Novel inhibitor of HIV-1 infection by blocking viral DNA nuclear entry |
|
| DCC4754 | Sk-575 | Highly potent and efficacious proteolysis targeting chimera (PROTAC) degrader of PARP1 for treating cancers, potently inhibiting the growth of cancer cells bearing BRCA1/2 mutations and inducing potent and specific degradation of PARP1 in various human ca |
|
| DCC4755 | Skf64346 Hydrochloride | Inhibitor of Aβ self-aggregation |
|
| DCC4756 | Skf-80723 Hydrobromide | Dopamine D1 receptor agonist |
|
